Investigational Drug Information for Azimilide
✉ Email this page to a colleague
What is the drug development status for Azimilide?
Azimilide is an investigational drug.
There have been 8 clinical trials for Azimilide.
The most recent clinical trial was a Phase 3 trial, which was initiated on September 1st 2001.
The most common disease conditions in clinical trials are Arrhythmias, Cardiac, Atrial Fibrillation, and Heart Failure. The leading clinical trial sponsors are Forest Laboratories, Warner Chilcott, and [disabled in preview].
Summary for Azimilide
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 963 |
| WIPO Patent Applications | 413 |
| Japanese Patent Applications | 151 |
| Clinical Trial Progress | Phase 3 (2001-09-01) |
| Vendors | 47 |
Recent Clinical Trials for Azimilide
| Title | Sponsor | Phase |
|---|---|---|
| Efficacy and Safety Study of Azimilide on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator (ICD) (SHIELD-2) | Forest Laboratories | Phase 3 |
| Effect of Azimilide Dihydrochloride on Renal Function | Forest Laboratories | Phase 1 |
| Effect of Azimilide Dihydrochloride on Renal Function | Warner Chilcott | Phase 1 |
Clinical Trial Summary for Azimilide
Top disease conditions for Azimilide
Top clinical trial sponsors for Azimilide
US Patents for Azimilide
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
